Impact of immune microenvironment on immune checkpoint inhibitor response in HER2-overexpressing urothelial carcinoma
Understanding immune patterns in a rare bladder cancer variant suggests combining two existing drug types could improve treatment effectiveness.
Transcriptomic analysis and small real-world cohort (n=29) suggest HER2-high urothelial carcinoma is characterized by Treg enrichment and low expression of canonical immune checkpoints, providing biological rationale for combining disitamab vedotin (RC48) with PD-1 inhibitors. These exploratory findings require larger prospective studies for confirmation.
What the study was
- Study design
- Bioinformatic analysis (TCGA + GEO) + IHC validation (n=21 specimens) + real-world cohort (n=29 RC48 ± PD-1 inhibitor)
- Population
- Patients with locally advanced or metastatic urothelial carcinoma with HER2 overexpression
- Sample size
- 29
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Discovery Oncology
Why it surfaced
RC48 (disitamab vedotin) is an approved antibody-drug conjugate in Asia for HER2+ UC; characterizing its immune context is clinically timely; small n and exploratory HER2-high definition limit conclusions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.